BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33944659)

  • 1. Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL.
    Cuesta-Mateos C; Juárez-Sánchez R; Mateu-Albero T; Loscertales J; Mol W; Terrón F; Muñoz-Calleja C
    MAbs; 2021; 13(1):1917484. PubMed ID: 33944659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.
    Mateu-Albero T; Juárez-Sánchez R; Loscertales J; Mol W; Terrón F; Muñoz-Calleja C; Cuesta-Mateos C
    Cancer Immunol Immunother; 2022 Mar; 71(3):627-636. PubMed ID: 34297159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target.
    Cuesta-Mateos C; Brown JR; Terrón F; Muñoz-Calleja C
    Front Immunol; 2021; 12():662866. PubMed ID: 33841445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia.
    Alfonso-Pérez M; López-Giral S; Quintana NE; Loscertales J; Martín-Jiménez P; Muñoz C
    J Leukoc Biol; 2006 Jun; 79(6):1157-65. PubMed ID: 16603585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax.
    Mateu-Albero T; Marcos-Jimenez A; Delgado-Wicke P; Terrón F; Loscertales J; López-Matencio JMS; Muñoz-Calleja C; Cuesta-Mateos C
    Hematol Oncol; 2023 Dec; 41(5):869-876. PubMed ID: 37545392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia.
    Cuesta-Mateos C; López-Giral S; Alfonso-Pérez M; de Soria VG; Loscertales J; Guasch-Vidal S; Beltrán AE; Zapata JM; Muñoz-Calleja C
    Exp Hematol; 2010 Sep; 38(9):756-64, 764.e1-4. PubMed ID: 20488224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.
    Ghobrial IM; Bone ND; Stenson MJ; Novak A; Hedin KE; Kay NE; Ansell SM
    Mayo Clin Proc; 2004 Mar; 79(3):318-25. PubMed ID: 15008605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia.
    Cuesta-Mateos C; Loscertales J; Kreutzman A; Colom-Fernández B; Portero-Sáinz I; Pérez-Villar JJ; Terrón F; Muñoz-Calleja C
    Cancer Immunol Immunother; 2015 Jun; 64(6):665-76. PubMed ID: 25724841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration.
    Redondo-Muñoz J; José Terol M; García-Marco JA; García-Pardo A
    Blood; 2008 Jan; 111(1):383-6. PubMed ID: 17890452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes.
    Till KJ; Lin K; Zuzel M; Cawley JC
    Blood; 2002 Apr; 99(8):2977-84. PubMed ID: 11929789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Ponader S; Chen SS; Buggy JJ; Balakrishnan K; Gandhi V; Wierda WG; Keating MJ; O'Brien S; Chiorazzi N; Burger JA
    Blood; 2012 Feb; 119(5):1182-9. PubMed ID: 22180443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells.
    Chunsong H; Yuling H; Li W; Jie X; Gang Z; Qiuping Z; Qingping G; Kejian Z; Li Q; Chang AE; Youxin J; Jinquan T
    J Immunol; 2006 Nov; 177(10):6713-22. PubMed ID: 17082584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-selectin controls trafficking of chronic lymphocytic leukemia cells in lymph node high endothelial venules in vivo.
    Lafouresse F; Bellard E; Laurent C; Moussion C; Fournié JJ; Ysebaert L; Girard JP
    Blood; 2015 Sep; 126(11):1336-45. PubMed ID: 26162407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia.
    Catusse J; Leick M; Groch M; Clark DJ; Buchner MV; Zirlik K; Burger M
    Mol Cancer; 2010 Nov; 9():297. PubMed ID: 21092185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nurselike cells sequester B cells in disorganized lymph nodes in chronic lymphocytic leukemia via alternative production of CCL21.
    Zaaboub R; Vimeux L; Contremoulins V; Cymbalista F; Lévy V; Donnadieu E; Varin-Blank N; Martin A; Dondi E
    Blood Adv; 2022 Aug; 6(16):4691-4704. PubMed ID: 35679464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia.
    Patrussi L; Capitani N; Martini V; Pizzi M; Trimarco V; Frezzato F; Marino F; Semenzato G; Trentin L; Baldari CT
    Cancer Res; 2015 Oct; 75(19):4153-63. PubMed ID: 26282174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma.
    Wiley HE; Gonzalez EB; Maki W; Wu MT; Hwang ST
    J Natl Cancer Inst; 2001 Nov; 93(21):1638-43. PubMed ID: 11698568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
    Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
    J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD62L as a therapeutic target in chronic lymphocytic leukemia.
    Burgess M; Gill D; Singhania R; Cheung C; Chambers L; Renyolds BA; Smith L; Mollee P; Saunders N; McMillan NA
    Clin Cancer Res; 2013 Oct; 19(20):5675-85. PubMed ID: 23948971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease.
    Mittal AK; Chaturvedi NK; Rai KJ; Gilling-Cutucache CE; Nordgren TM; Moragues M; Lu R; Opavsky R; Bociek GR; Weisenburger DD; Iqbal J; Joshi SS
    Mol Med; 2014 Jul; 20(1):290-301. PubMed ID: 24800836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.